News for Healthier Living
Mount Sinai to Lead National Trial of Targeted Therapy for Infants With Noonan Syndrome and Severe Hypertrophic Cardiomyopathy
Researchers at the Icahn School of Medicine at Mount Sinai will lead a new national clinical trial evaluating a precision medicine approach for infants with Noonan syndrome and related conditions who develop severe hypertrophic cardiomyopathy, a potentially life-threatening condition in which the heart muscle becomes abnormally thick.
October 21, 2026
October 30 2026October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026October 18 2026October 17 2026October 16 2026
|
|
|
|
|